Exploiting bacterial DNA gyrase as a drug target: current state and perspectives

DNA gyrase is a type II topoisomerase that can introduce negative supercoils into DNA at the expense of ATP hydrolysis. It is essential in all bacteria but absent from higher eukaryotes, making it an attractive target for antibacterials. The fluoroquinolones are examples of very successful gyrase-ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Collin, Frédéric, Karkare, Shantanu, Maxwell, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189412/
https://www.ncbi.nlm.nih.gov/pubmed/21904817
http://dx.doi.org/10.1007/s00253-011-3557-z
_version_ 1782213467721170944
author Collin, Frédéric
Karkare, Shantanu
Maxwell, Anthony
author_facet Collin, Frédéric
Karkare, Shantanu
Maxwell, Anthony
author_sort Collin, Frédéric
collection PubMed
description DNA gyrase is a type II topoisomerase that can introduce negative supercoils into DNA at the expense of ATP hydrolysis. It is essential in all bacteria but absent from higher eukaryotes, making it an attractive target for antibacterials. The fluoroquinolones are examples of very successful gyrase-targeted drugs, but the rise in bacterial resistance to these agents means that we not only need to seek new compounds, but also new modes of inhibition of this enzyme. We review known gyrase-specific drugs and toxins and assess the prospects for developing new antibacterials targeted to this enzyme.
format Online
Article
Text
id pubmed-3189412
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31894122011-10-12 Exploiting bacterial DNA gyrase as a drug target: current state and perspectives Collin, Frédéric Karkare, Shantanu Maxwell, Anthony Appl Microbiol Biotechnol Mini-Review DNA gyrase is a type II topoisomerase that can introduce negative supercoils into DNA at the expense of ATP hydrolysis. It is essential in all bacteria but absent from higher eukaryotes, making it an attractive target for antibacterials. The fluoroquinolones are examples of very successful gyrase-targeted drugs, but the rise in bacterial resistance to these agents means that we not only need to seek new compounds, but also new modes of inhibition of this enzyme. We review known gyrase-specific drugs and toxins and assess the prospects for developing new antibacterials targeted to this enzyme. Springer-Verlag 2011-09-09 2011 /pmc/articles/PMC3189412/ /pubmed/21904817 http://dx.doi.org/10.1007/s00253-011-3557-z Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Mini-Review
Collin, Frédéric
Karkare, Shantanu
Maxwell, Anthony
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
title Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
title_full Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
title_fullStr Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
title_full_unstemmed Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
title_short Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
title_sort exploiting bacterial dna gyrase as a drug target: current state and perspectives
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189412/
https://www.ncbi.nlm.nih.gov/pubmed/21904817
http://dx.doi.org/10.1007/s00253-011-3557-z
work_keys_str_mv AT collinfrederic exploitingbacterialdnagyraseasadrugtargetcurrentstateandperspectives
AT karkareshantanu exploitingbacterialdnagyraseasadrugtargetcurrentstateandperspectives
AT maxwellanthony exploitingbacterialdnagyraseasadrugtargetcurrentstateandperspectives

Ejemplares similares